Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study.
Vision in a Phase 3 Trial of Natalizumab for Multiple Sclerosis: Relation to Disability and Quality of Life.
Product Insert, Amiloride HCl Tablets
Cystoid macular edema associated with fingolimod use for multiple sclerosis.
Vitamin D: a natural inhibitor of multiple sclerosis.
IFN-γ Signaling to Astrocytes Protects from Autoimmune Mediated Neurological Disability.
The use of aminopyridines in neurological disorders.
ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
CD4 cell response to interval therapy with natalizumab.
Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis.
Age-dependent effects on the treatment response of natalizumab in MS patients.
Biotechnology industry leader Centocor Ortho Biotech is now Janssen Biotech, Inc., part of the Janssen pharmaceutical companies
Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
RNF and Betaseron® Tolerability Study (REFORMS)
Multiple sclerosis causing a partial sixth nerve palsy.
New Drug Review 2010: Ustekinumab (Stelara, Centocor Ortho Biotech)
Axonal transport analysis using Multitemporal Association Tracking.
Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses.
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis.
Young Researchers in Life Sciences Meeting 2012
IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
The occurrence of dystonia in upper-limb multiple sclerosis tremor.
Pages
« first
‹ previous
…
167
168
169
170
171
172
173
174
175
…
next ›
last »